Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026, for BioMarin Pharmaceutical Inc. The reporting period is significantly impacted by the completion of the acquisition of Amicus Therapeutics, Inc. on April 27, 2026. The acquisition added two commercial products (GALAFOLD and POMBILITI + OPFOLDA) and a Phase 3 asset (BMN 820) to BioMarin's portfolio. The company operates as a single business segment focused on rare disease therapies.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $989.7 million | $1,755.9 million |
| Net Income | $44.8 million | $150.3 million |
| Diluted EPS | $0.23 | $0.77 |
| Gross Margin | 79.5% | 77.3% |
| Operating Cash Flow (6mo) | $388.8 million | $388.8 million |
| Total Debt (Principal) | $4.3 billion | $4.3 billion |
| Cash & Equivalents | $874.0 million | $874.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 20% year-over-year for the quarter and 12% for the six-month period. This growth was driven by the inclusion of Amicus products (GALAFOLD and POMBILITI + OPFOLDA) and higher sales volumes for VOXZOGO and PALYNZIQ.
- Profitability Decline: Net income decreased significantly, dropping from $240.5 million to $44.8 million for the quarter and from $426.2 million to $150.3 million for the six-month period. This decline is primarily due to increased interest expense from acquisition financing, higher intangible asset amortization ($73.5 million vs. $4.8 million in the prior quarter), and restructuring charges.
- Debt Expansion: Total indebtedness increased from $600 million at year-end 2025 to $4.3 billion as of June 30, 2026, to fund the $5.3 billion Amicus acquisition. This included new senior unsecured notes and term loans.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose sharply to $395.5 million for the quarter (up from $232.3 million) due to integration costs, restructuring charges ($56.4 million), and transaction expenses. R&D expenses also increased to $207.0 million.
Guidance, Outlook, and Risks
- Outlook: Management expects interest expense to increase over the next 12 months due to new debt financings. Amortization of intangible assets is also expected to increase. The company anticipates cash generated from operations and existing liquidity will satisfy requirements for at least the next 12 months.
- Restructuring: The company committed to a restructuring plan for Amicus integration, expecting pre-tax charges of approximately $92.0 million, with severance actions expected to be completed in phases through April 2027.
- Key Risks:
- Integration Risk: Failure to realize anticipated synergies or accurately forecast the performance of the combined company.
- Debt Servicing: Increased leverage limits financial flexibility and requires significant cash flow for interest and principal payments, including the 2027 Notes maturing in May 2027.
- Regulatory & Pricing: Risks related to government price controls, reimbursement challenges, and the impact of the Inflation Reduction Act (IRA) on drug pricing.
- Macroeconomic Factors: Exposure to foreign currency fluctuations, geopolitical instability, and potential tariffs on pharmaceutical imports.
Investor Verification Checklist
- Verify the final purchase price allocation for the Amicus acquisition, specifically the valuation of intangible assets and goodwill, as preliminary estimates may be revised.
- Monitor the company's ability to meet debt covenants, specifically the Total Net Leverage Ratio (max 3.50:1) and Interest Coverage Ratio (min 3.00:1) under the 2026 Credit Agreement.
- Assess the timeline and success of the integration of Amicus' commercial products (GALAFOLD, POMBILITI + OPFOLDA) and the development of BMN 820.
- Review the impact of the $92.0 million restructuring plan on future operating expenses and cash flow.
- Track the status of the DOJ investigation regarding sponsored testing programs for VIMIZIM and NAGLAZYME.